C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial

Reuters2026/09/04 06:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

C4X Discovery to receive a $13 million milestone payment from AstraZeneca on 4 September 2026.
Payment triggered by AstraZeneca advancing AZD4916, an oral NRF2 activator licensed from C4X Discovery, into Phase I.
Deal signed in November 2022 provides up to $400 million in preclinical and clinical milestones.
Agreement also includes tiered mid-single digit royalties on future sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4X Discovery Holdings Ltd. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial

You may also like

Crypto prices